Drug intelligence / Profile preview

PAN006

Development stage: Preclinical
Lead developer: Pantherna Therapeutics
Modality: mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems

Overview

PAN006 is an mRNA-based therapeutic candidate developed by Pantherna Therapeutics for the treatment of Acute Respiratory Distress Syndrome (ARDS) and COVID-19 pneumonia. The drug utilizes Pantherna's proprietary mRNA platform to target the Tie2 (TEK tyrosine kinase, endothelial) receptor. By modulating the Tie2/Angiopoietin-1 (Ang1) pathway, PAN006 aims to stabilize the vascular endothelium and reduce vascular leakage, which is a hallmark of severe pulmonary inflammation and respiratory failure. It is currently in preclinical development.

Targets

TEK (Angiopoietin-1 receptor)

Beyond the preview

Go deeper on PAN006.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PAN006.

Explore the full profile